共 50 条
- [1] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC)JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Schnadig, Ian D.Modiano, Manuel R.Poma, AllenHedley, Mary LynneMartell, Robert E.Schwartzberg, Lee Steven
- [2] ROLAPITANT, A NOVEL NK-1 RECEPTOR ANTAGONIST (NK1-RA), PHASE 3 TRIAL RESULTS IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SUBJECTS RECEIVING HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY (HEC AND MEC).ONCOLOGY NURSING FORUM, 2015, 42 (02) : E222 - E223Clark-Snow, RebeccaNagy, CindyArora, SujataPoma, AllenNavari, Rudolph
- [3] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Rapoport, Bernardo LeonPoma, AllenHedley, Mary LynneMartell, Robert E.Navari, Rudolph M.
- [4] Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)Supportive Care in Cancer, 2015, 23 : 3281 - 3288Bernardo RapoportDaniel ChuaAllen PomaSujata AroraYan WangLuis Enrique Fein
- [5] Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)SUPPORTIVE CARE IN CANCER, 2015, 23 (11) : 3281 - 3288Rapoport, BernardoChua, DanielPoma, AllenArora, SujataWang, YanFein, Luis Enrique
- [6] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)Rapoport, Bernardo LeonSchwartzberg, Lee StevenChasen, Martin RobertPowers, DanielArora, SujataNavari, Rudolph M.Schnadig, Ian D.
- [8] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Hesketh, Paul JosephSchwartzberg, Lee StevenModiano, Manuel R.Arora, SujataPoma, AllenSchnadig, Ian D.
- [9] LIKELIHOOD OF A SUBSEQUENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) EVENT IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)VALUE IN HEALTH, 2010, 13 (07) : A251 - A251Feinberg, B.Gilmore, J.Haislip, S.Jackson, J.Jain, G.Balu, S.Buchner, D.
- [10] Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV): Efficacy and safety over multiple cycles of highly or moderately emetogenic chemotherapyEUROPEAN JOURNAL OF CANCER, 2015, 51 : S212 - S213Rapoport, B.Schwartzberg, L.Chasen, M.Poma, A.Arora, S.Navari, R.Schnadig, I.